Stuart Diamond: ApoB as a Key Marker of Cardiovascular Risk
Stuart Diamond, Scientific Director at Global Integral Beauty, Medical Doctor at Geneva College of Longevity Science, and Co-Founder at Equilux – Unlock Your Biology, shared a post on LinkedIn:
“For decades, cardiovascular risk has been assessed primarily through LDL-cholesterol.
But modern lipid science increasingly points to a more fundamental driver of atherosclerosis:
Apolipoprotein B (ApoB).
Every atherogenic lipoprotein particle – LDL, VLDL remnants, IDL, and Lp(a) – carries one ApoB molecule.
This means ApoB reflects the number of particles capable of penetrating the arterial wall and initiating plaque formation.
Two individuals can have identical LDL- C levels, yet one may have significantly more circulating atherogenic particles.
In simple terms:
- LDL-C measures cholesterol content.
- ApoB measures particle number.
Evidence continues to support this.
- Ference BA et al., European Heart Journal (2017) — genetic analyses showing cardiovascular risk proportional to cumulative exposure to ApoB lipoproteins.
- Sniderman AD et al., JAMA Cardiology (2019) — ApoB more accurately reflects atherogenic particle burden than LDL-C.
- Yusuf S et al., Lancet — INTERHEART study linking ApoB/ApoA1 ratio to myocardial infarction risk globally.
From a biological perspective the mechanism is straightforward.
Atherosclerosis begins when ApoB-containing lipoproteins cross the endothelium and become retained in the arterial intima, triggering inflammation and plaque formation.
The greater the number of circulating ApoB particles, the greater the probability of this process occurring.
Cardiovascular disease still remains the leading cause of mortality worldwide, often developing silently for decades.
Monitoring ApoB allows clinicians to detect and address risk earlier and more precisely.
Preventive targets commonly used in cardiology practices include:
- ApoB less than 80 mg/dL – moderate risk
- ApoB less than 60 mg/dL – high-risk prevention
- ApoB less than 50 mg/dL – aggressive prevention
Achieving these levels often requires lifestyle optimization and targeted therapy including statins, ezetimibe, PCSK9 inhibitors, or bempedoic acid.
What is becoming increasingly clear:
Atherosclerosis is fundamentally a disease of cumulative exposure to ApoB-containing particles.
Reducing that exposure earlier in life may be one of the most powerful ways to extend cardiovascular health and healthspan.”
Stay updated with Hemostasis Today.
-
Apr 25, 2026, 17:10Abdul Mannan: 10-Minute FVIII Inhibitor Screening Test
-
Apr 25, 2026, 16:55Connie Montgomery: Highlights from the Hemophilia Federation of America Symposium 2026
-
Apr 25, 2026, 16:35Fernanda Aspilche: Bringing the Alpha-1 Community to the European Parliament
-
Apr 25, 2026, 15:49Brian O Mahony: Expanding the Non-Replacement Therapy Toolbox
-
Apr 25, 2026, 15:44Toong Youttananukorn: Six Abstracts Demonstrate the Impact of WBDR at WFH Congress 2026
-
Apr 25, 2026, 15:08Lakmali Silva: Just Back from a Truly Energising Days in the UNC 12th Symposium on Hemostasis
-
Apr 25, 2026, 15:08Peripheral Blood Smear (PBS) Under the Microscope: Bridging Morphology and Hematology
-
Apr 25, 2026, 15:06Pushpendra Dwivedi: Blood Availability as One of Those Silent Problems No One Notices, Until It’s Too Late
-
Apr 25, 2026, 15:05Faheema Hasan: Chronic Methemoglobinemia Causing Longstanding Tissue Hypoxia and Secondary Erythrocytosis